Oncology CRA
Track the site’s specimen and test records and reconcile prior targeted-therapy dates where the cohort requires them.
Oncology trial operations
For a biomarker-selected non-small cell lung cancer (NSCLC) cohort, a patient may arrive with a local report while the study still needs a specified assay, specimen, or central confirmation. Build the screening plan around the result the protocol accepts.
NSCLC studies can differ by histology, stage, molecular profile, and previous treatment. When a protocol requires a particular tissue specimen or assay, tissue availability, adequacy, and result turnaround shape the screening workload. In perioperative or post-chemoradiation cohorts, procedure and treatment completion dates can add a separate scheduling dependency.
Separate the local finding, specimen status, and qualifying result in the tracker. Have the CRA check the tissue and report records against the protocol. Have the CTM agree on the lab contact, turnaround expectations, and timing for escalation to the designated eligibility reviewer.
When this handoff needs a sponsor decision, use an executive briefing to clarify who owns it and what evidence will guide the decision.
Request an executive briefing →Track the site’s specimen and test records and reconcile prior targeted-therapy dates where the cohort requires them.
Agree on tissue routing, turnaround expectations, and the escalation point for an inadequate specimen or pending result.
Separate tissue inadequacy, lab turnaround, and handoff delays across sites, including recurring misses after surgery or chemoradiation.
A Lead CRA can coordinate recurring findings. For scoped SIGNAL Managed Monitoring, a named review lead brings patterns and open actions to the sponsor’s decision owners.